FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)

View source ↗

Summary

FDA approved a supplemental application for paroxetine (Padagis US LLC), updating the labeling to reflect expanded indications for the antidepressant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder
• Major Depressive Disorder
• Obsessive-compulsive Disorder
• Panic Disorder
• Post-traumatic Stress Disorder
• Premenstrual Dysphoric Disorder
• Social Anxiety Disorder

Drugs mentioned

• Paroxetine (Paroxetine hydrochloride)

Snippet

SUPPL AP for PAROXETINE (PAROXETINE)